Large Cell Neuroendocrine Carcinoma (LCNEC) of the Lung: First-Line Treatment Approach

Classification and Treatment Framework

• The National Comprehensive Cancer Network (NCCN) guidelines explicitly direct that LCNEC be managed using Non-Small Cell Lung Cancer treatment algorithms, not small cell lung cancer protocols 1, 2, 3

Stage-Specific Treatment Algorithm

Early Stage Disease (Stage I-IIIA)

• Surgery with lobectomy is the primary treatment for resectable LCNEC, with systematic nodal dissection mandatory during surgery 1, 2, 3, 5
• Mediastinal staging must be performed before resection to rule out occult nodal disease 1, 3
• Adjuvant platinum-based chemotherapy is recommended after complete resection 1, 3, 4

Advanced/Metastatic Disease (Stage IV)

• Platinum-based chemotherapy combined with etoposide is the standard first-line treatment for stage IV LCNEC 4
• The primary regimen is cisplatin plus etoposide, with carboplatin plus etoposide as an alternative for cisplatin-intolerant patients 4, 6

Molecular Testing Requirements

• Comprehensive molecular testing must be performed before initiating any systemic therapy to identify potentially actionable alterations 8
• Testing should include EGFR mutations, ALK rearrangements, ROS1 rearrangements, BRAF V600E mutations, MET exon 14 skipping mutations, RET rearrangements, NTRK rearrangements, and PD-L1 expression by immunohistochemistry 8

Palliative and Supportive Measures

• All patients with advanced LCNEC should be referred to interdisciplinary palliative care teams early in the disease course, alongside active cancer treatment 8
• Additional supportive measures include somatostatin analogs for symptom control, external beam radiotherapy for bone metastases, ablative therapies for limited metastatic disease, and management of malignant pleural or pericardial effusions 4, 5, 8

Performance Status Considerations

• For patients with ECOG performance status 0-2, platinum-based chemotherapy should be offered 8, 9
• For patients with ECOG performance status 3-4, best supportive care or single-agent chemotherapy may be considered, though cytotoxic treatment benefit is limited 7, 8

Common Pitfalls to Avoid

• Do not treat LCNEC with SCLC protocols despite its neuroendocrine classification—NCCN explicitly directs use of NSCLC guidelines 1, 2, 3
• Do not skip molecular testing—rare actionable mutations may be present that would change first-line treatment 8

Prognosis and Surveillance

• Follow-up examinations should occur every 3-4 months during years 1-2 with chest CT imaging, decreasing in frequency during subsequent years 1, 3